Sep. 1 at 10:40 AM
Citizens reitd
$IDYA Mkt OP-
$42 /said -- IDEAYA's rapid advancement of IDE849 through the clinic is a strong indicator of the company's conviction in the program.
$AZN $AMGN ZLAB MRK - DSNKY
Citizens added—This confidence is supported by findings from Hengrui's ongoing Chinese Phase 1 study, as well as emerging experience from IDYA's own open-label, first-in-Western-humans Phase 1 study, for which data are currently undisclosed.
While updated efficacy and durability data from Hengrui at ESMO 2026 and the initial Western dataset in 2H26 remain important catalysts, we view the positive FDA interactions, growing clarity around the registrational strategy, and alignment on a Phase 3 study with a potential accelerated approval pathway as constructive developments for the program.
While the first registrational study focuses on IDE849 monotherapy, IDYA is evaluating combination studies with either PD-1 inhibitor, Imfinzi (durvalumab), from AZN or with internally developed PARG inhibitor, IDE161.
